CAJ | 학술논문

目的：观察二丁酰环磷腺苷钙联合生脉、黄芪注射液治疗慢性心力衰竭（ chronic heart failure, CHF)的临床效果。方法将80例CHF随机分为研究组和对照组,每组40例。对照组予强心、利尿等常规抗心力衰竭治疗,研究组在常规治疗基础上予二丁酰环磷腺苷钙联合生脉、黄芪注射液治疗。疗程均为2周,疗程结束后比较两组疗效。结果研究组、对照组治疗后心功能均有所改善,总有效率分别为95．0%、80．0%,差异有统计学意义（ P <0．05)；6 min步行试验总有效率分别为87．5%、75．0%,差异有统计学意义（P<0．05)。治疗后两组N末端B型利钠肽前体（NT-pro BNP)水平均有所下降（P<0．01),研究组较对照组下降更为明显（P<0．05)；两组左心室舒张末内径（LVEDD)较治疗前均缩小（P<0．05),左心室射血分数（LVEF)、心输出量（CO)均较治疗前提高（P<0．05),研究组上述指标改善优于对照组（P<0．01)。两组治疗中均未发现明显不良反应。结论二丁酰环磷腺苷钙联合生脉、黄芪注射液治疗CHF能更好地改善心功能,提高患者的生活质量。
목적：관찰이정선배린선감개연합생맥、황기주사액치료만성심력쇠갈（ chronic heart failure, CHF)적림상효과。방법장80례CHF수궤분위연구조화대조조,매조40례。대조조여강심、이뇨등상규항심력쇠갈치료,연구조재상규치료기출상여이정선배린선감개연합생맥、황기주사액치료。료정균위2주,료정결속후비교량조료효。결과연구조、대조조치료후심공능균유소개선,총유효솔분별위95．0%、80．0%,차이유통계학의의（ P <0．05)；6 min보행시험총유효솔분별위87．5%、75．0%,차이유통계학의의（P<0．05)。치료후량조N말단B형리납태전체（NT-pro BNP)수평균유소하강（P<0．01),연구조교대조조하강경위명현（P<0．05)；량조좌심실서장말내경（LVEDD)교치료전균축소（P<0．05),좌심실사혈분수（LVEF)、심수출량（CO)균교치료전제고（P<0．05),연구조상술지표개선우우대조조（P<0．01)。량조치료중균미발현명현불량반응。결론이정선배린선감개연합생맥、황기주사액치료CHF능경호지개선심공능,제고환자적생활질량。
Objective To observe the clinical effect of Caleium dibulyryl cyclic adenosine monophate and Sheng-mai injection and Astragalus injection to treat chronic heart failure ( CHF) . Methods 80 patients with CHF were randomly divid-ed into two groups (n=40); control group was given conventional heart failure (cardiac, diuretic) treatment. Study group (n=40), in addition to the conventional therapy, was given the Caleium dibulyryl cyclic adenosine monophate Sheng-mai in-jection, and Astragalus injection. The course of treatment of the two groups was two weeks. The efficacy of treatment was com-pared. Results The heart function of the two groups after treatment was improved. The total efficiency of the study group was 95. 0% while the control group was 80. 0%(P<0. 05). The result of 6min walk test:The total efficiency of the study group was 87. 5%, while the control group was 75. 0%. The difference was statistically significant(P<0. 05). The comparison of plasma NT-pro BNP levels: After 2 weeks of treatment, the NT-pro BNP levels of the two groups were decreased, and the study group was more significantly than control group. The difference was statistically significant(P<0. 05). After 2 weeks of treatment, the LVEPO of both groups was reduced. The LVEF and CO were improved(P<0. 05). The study group was better than the control group and the difference was statistically significant(P<0. 01). The two groups were not found with signifi-cant adverse reactions. Conclusion Caleium dibulyryl cyclic adenosine monophate and Sheng-mai injection and Astragalus injection in treatment of chronic heart failure is safe and effective in improving heart function with good prognosis and better quality of life.